ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Tsubota Laboratory, Inc. engages in research and development of pharmaceuticals and medical devices related to the treatment of myopia, dry eye, presbyopia, and related cases. The company was founded by Kazuo Tsubota on May 28, 2012 and is headquartered in Tokyo, Japan.

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Kowa Co., Ltd. engages in trading of textiles, machinery, and construction materials. The company also manufactures and sells medicines, medical equipment, and energy saving products. It operates through the following business divisions: Pharmaceutical, Medical Device, Foods, General Trading, Lifestyle Business, and Hospitality. The company was founded on December 25, 1894 and is headquartered in Nagoya, Japan.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Chengdu Dayinhai Eye Hospital Co., Ltd. was established on February 17, 2016. The legal representative is Duan Junguo. The business scope of the company includes: eye hospital services, ear nose throat hospital services, stomatology hospital services, cardiovascular medicine hospital services, respiratory medicine hospital services, endocrine department hospital services, digestive medicine hospital services, beauty and plastic surgery hospital services, acupuncture and massage, rehabilitation, elderly care services, health management related consulting and services; R&D and sales of drugs and medical equipment, medical technology services, medical software R&D and sales, etc. Chengdu Dayinhai Ophthalmic Hospital Co., Ltd. is a large research hospital integrating medicine, teaching and research. The hospital is located in Xinghui West Road, which is on the bank of Fuhe River in Chengdu. It is built according to the national standard of Grade III Grade A specialized hospital. It covers an area of nearly 40 mu, with a building area of 56000 square meters, 400 beds and 127 open beds in Phase I. The hospital is equipped with advanced professional ophthalmic equipment. We gathered many experts and scholars from both Chinese and Western medicine at home and abroad to serve as the academic and technical leaders in various professional fields of the hospital, providing high-quality services to the majority of eye patients. The ophthalmic hospital will be characterized by traditional Chinese medicine, reflecting the combination of traditional Chinese and western medicine, ophthalmology and optometry, eye and systemic diseases, ophthalmology and the Internet, medical treatment and teaching and scientific research, and will be built into a modern ophthalmic medical institution with international standards, outstanding characteristics and integrated prevention and treatment. The hospital has set up six major centers, including the Traditional Chinese Medicine Ophthalmology Center, the Fundus Disease Center, the diabetes Retinopathy Prevention and Treatment Center, the Cataract Refraction Center, the Eye Vision Center, and the eye shadow Image Analysis and Diagnosis Center. It has set up 17 specialized departments, including cataract, glaucoma, diabetes retinopathy, fundus medicine, fundus surgery, uveitis, corneal disease, refractive surgery, strabismus and amblyopia, myopia prevention and control, orbital disease, dry eye, and lacrimal duct disease. In clinical practice, combining the advantages of traditional Chinese medicine and modern medicine, while giving full play to the simple, convenient, effective and inexpensive features of traditional Chinese medicine, such as oral administration, external application, fumigation, atomization, acupuncture, moxibustion, massage, massage, etc., full femtosecond laser and laser myopia correction, 3D femtosecond laser cataract surgery, cataract phacoemulsification, ICL and triple focus refractive surgery, vitrectomy, trabeculectomy Corneal transplantation, strabismus correction, non-invasive reconstruction of lacrimal passage, eye plastic surgery, medical optometry, amblyopia correction, low vision rehabilitation, visual function training and other modern medical diagnosis and treatment projects provide excellent medical and health care services for patients with eye diseases in western China.

Green Cross Co., Ltd. engages in the manufacture, sale, and rental of safety items. Its products include road safety materials, disaster prevention necessities, safety equipment, protection gear, and signboards and tags. The company was founded in January 1969 and is headquartered in Fukuoka, Japan.

Freedom Meditech is a private, growth-stage medical device company focused on the development and commercialization of first-to-market, non-invasive, ophthalmic medical devices for both chronic disease detection (ClearPath DS-120) and the management of diabetes (I-SugarX). The hallmark of their product portfolio is to provide “free and healthy” alternatives to existing diagnostic tools on the market for the detection, monitoring and management of chronic diseases.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

AGC, Inc. engages in the manufacture and sale of glass, electronic materials, and chemicals. It operates through the following segments: Glass, Electronics, Chemicals, Ceramics and Other. The Glass segment provides security glass, fire-resistant glass, heat insulating glass, and automotive glass. The Electronics segment offers glass for display panels, optical thin film products, opto-electronic materials, synthetic quartz products, semiconductor components, and lighting products. The Chemicals segment deals with chlor-alkali and urethane products, water and oil repellents, solvents, gases, and specialty chemicals. The Ceramics and Other segment includes ceramic products, logistics, and financial services. The company was founded by Toshiya Iwasaki on September 8, 1907 and is headquartered in Tokyo, Japan.

Daiichi Seiyaku Co., Ltd. engaged in the manufacture, sale research and development of medicine. The company was founded on October 1, 1915 and was headquartered in Tokyo, Japan.

Stealth BioTherapeutics, Inc., part of Stealth BioTherapeutics Corp., is a company headquartered in Newton, MA, that develops therapies to treat the mitochondrial dysfunctions and age-related diseases. The firm was founded in 2007. Irene P. McCarthy is the current CEO, occupying that position since 2009.\nThe company says this about itself: The Company is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. The Company believes that its lead product candidate, elamipretide, has the potential to treat ophthalmic diseases, such as dry AMD, rare neuromuscular disorders, such as primary mitochondrial myopathy, and rare cardiomyopathies, such as Barth syndrome. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.